Syros Pharmaceuticals Analyst Ratings
Syros Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a reiterated with a price target of $0.00 to $15.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $3.66, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 309.84% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/11/2023 | 309.84% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/11/2023 | 309.84% | JMP Securities | $16 → $15 | Maintains | Market Outperform |
| 03/03/2023 | 255.19% | Oppenheimer | $15 → $13 | Maintains | Outperform |
| 03/03/2023 | 309.84% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 01/05/2023 | 446.45% | Piper Sandler | $27 → $20 | Maintains | Overweight |
| 11/15/2022 | 337.16% | JMP Securities | $40 → $16 | Maintains | Market Outperform |
| 11/15/2022 | 309.84% | Oppenheimer | $30 → $15 | Maintains | Outperform |
| 11/15/2022 | 446.45% | HC Wainwright & Co. | $6 → $20 | Maintains | Buy |
| 08/10/2022 | -18.03% | Oppenheimer | $9 → $3 | Maintains | Outperform |
| 07/12/2022 | 63.93% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 05/17/2022 | 173.22% | HC Wainwright & Co. | $15 → $10 | Maintains | Buy |
| 05/17/2022 | 173.22% | Alliance Global Partners | $14 → $10 | Maintains | Buy |
| 09/23/2021 | 528.42% | Roth Capital | $20 → $23 | Maintains | Buy |
| 11/04/2020 | 309.84% | HC Wainwright & Co. | $11 → $15 | Upgrades | Neutral → Buy |
| 03/06/2020 | 118.58% | HC Wainwright & Co. | $10 → $8 | Reiterates | → Neutral |
| 01/17/2020 | 145.9% | Wedbush | → $9 | Downgrades | Outperform → Neutral |
| 10/18/2019 | 337.16% | JMP Securities | $18 → $16 | Maintains | Market Outperform |
| 02/14/2019 | — | Oppenheimer | Assumes | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 309.84% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 05/11/2023 | 309.84% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 05/11/2023 | 309.84% | JMP 證券 | 16 美元 → 15 美元 | 維護 | 市場表現跑贏大盤 |
| 03/03/2023 | 255.19% | 奧本海默 | 15 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 03/03/2023 | 309.84% | HC Wainwright & Co. | → 15 美元 | 重申 | → 購買 |
| 01/05/2023 | 446.45% | 派珀·桑德勒 | 27 美元 → 20 美元 | 維護 | 超重 |
| 11/15/2022 | 337.16% | JMP 證券 | 40 美元 → 16 美元 | 維護 | 市場表現跑贏大盤 |
| 11/15/2022 | 309.84% | 奧本海默 | 30 美元 → 15 美元 | 維護 | 跑贏大盤 |
| 11/15/2022 | 446.45% | HC Wainwright & Co. | 6 美元 → 20 美元 | 維護 | 購買 |
| 08/10/2022 | -18.03% | 奧本海默 | 9 美元 → 3 美元 | 維護 | 跑贏大盤 |
| 2022 年 12 月 7 日 | 63.93% | HC Wainwright & Co. | 10 美元 → 6 美元 | 維護 | 購買 |
| 05/17/2022 | 173.22% | HC Wainwright & Co. | 15 美元 → 10 美元 | 維護 | 購買 |
| 05/17/2022 | 173.22% | 聯盟全球合作伙伴 | 14 美元 → 10 美元 | 維護 | 購買 |
| 2021 年 9 月 23 日 | 528.42% | 羅斯資本 | 20 美元 → 23 美元 | 維護 | 購買 |
| 2020 年 4 月 11 日 | 309.84% | HC Wainwright & Co. | 11 美元 → 15 美元 | 升級 | 中性 → 買入 |
| 03/06/2020 | 118.58% | HC Wainwright & Co. | 10 美元 → 8 美元 | 重申 | → 中立 |
| 2020 年 1 月 17 日 | 145.9% | Wedbush | → 9 美元 | 降級 | 跑贏大盤 → 中性 |
| 10/18/2019 | 337.16% | JMP 證券 | 18 美元 → 16 美元 | 維護 | 市場表現跑贏大盤 |
| 02/14/2019 | — | 奧本海默 | 假設 | → 跑贏大盤 |
What is the target price for Syros Pharmaceuticals (SYRS)?
錫羅斯製藥公司（SYRS）的目標價格是多少？
The latest price target for Syros Pharmaceuticals (NASDAQ: SYRS) was reported by HC Wainwright & Co. on August 9, 2023. The analyst firm set a price target for $15.00 expecting SYRS to rise to within 12 months (a possible 309.84% upside). 10 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月9日公佈了Syros Pharmicals（納斯達克股票代碼：SYRS）的最新目標股價。這家分析公司將目標股價定爲15.00美元，預計SYRS將在12個月內升至15.00美元（可能上漲309.84％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Syros Pharmaceuticals (SYRS)?
分析師對賽羅斯製藥公司（SYRS）的最新評級是多少？
The latest analyst rating for Syros Pharmaceuticals (NASDAQ: SYRS) was provided by HC Wainwright & Co., and Syros Pharmaceuticals reiterated their buy rating.
Syros Pharmicals（納斯達克股票代碼：SYRS）的最新分析師評級由HC Wainwright & Co. 提供，Syros Pharmicals重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Syros Pharmaceuticals (SYRS)?
Syros Pharmicals（SYRS）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syros Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syros Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Syros Pharmicals的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Syros Pharmicals的最新評級是在2023年8月9日提交的，因此您應該預計下一個評級將在2024年8月9日左右公佈。
Is the Analyst Rating Syros Pharmaceuticals (SYRS) correct?
分析師對錫羅斯製藥公司 (SYRS) 的評級是否正確？
While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a reiterated with a price target of $0.00 to $15.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $3.66, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的賽羅斯製藥公司（SYRS）評級得到了重申，目標股價爲0.00美元至15.00美元。Syros Pharmicals（SYRS）目前的交易價格爲3.66美元，在分析師的預測區間內。
